



(11) **EP 2 729 464 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07D 417/12<sup>(2006.01)</sup>**

(86) International application number:  
**PCT/EP2012/062867**

(48) Corrigendum issued on:  
**17.06.2015 Bulletin 2015/25**

(87) International publication number:  
**WO 2013/004676 (10.01.2013 Gazette 2013/02)**

(45) Date of publication and mention  
of the grant of the patent:  
**29.04.2015 Bulletin 2015/18**

(21) Application number: **12731448.2**

(22) Date of filing: **03.07.2012**

(54) **CYCLOPROPYL-FUSED-1,3-THIAZEPINES AS BACE 1 AND/OR BACE 2 INHIBITORS**

CYCLOPROPYL-KONDENSIERTE-1,3-THIAZEPINE ALS BACE 1- UND/ODER BACE-2-HEMMER  
1,3-THIAZÉPINES À CYCLOPROPYLE FUSIONNÉ EN TANT QU'INHIBITEURS DE BACE 1 ET/OU  
DE BACE 2

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(72) Inventor: **WOLTERING, Thomas**  
**79104 Freiburg (DE)**

(30) Priority: **06.07.2011 EP 11172784**

(74) Representative: **Müller-Afraz, Simona**  
**F. Hoffmann-La Roche AG**  
**CLP - Patent Department**  
**Grenzacherstrasse 124**  
**4070 Basel (CH)**

(43) Date of publication of application:  
**14.05.2014 Bulletin 2014/20**

(56) References cited:  
**WO-A1-2011/005738 WO-A1-2011/029803**

(73) Proprietors:  
• **F. Hoffmann-La Roche AG**  
**4070 Basel (CH)**  
• **Siena Biotech S.p.a.**  
**53100 Siena (IT)**

**EP 2 729 464 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).